skip to main content

After clinical trial hold and plunging stock, what's next for Juno Therapeutics?

Bill Radke speaks with Luke Timmerman about what went wrong during Seattle-based Juno Therapeutics' clinical trial of an immunotherapy treatment for leukemia and what it might mean for the company.